Mitoxantrone and abacavir: An ALK protein-targeted < i > in silico < /i > proposal for the treatment of non-small cell lung cancer

This study proposes FDA-approved drugs with ALK inhibitory characteristics. Moreover, we identified pharmacophores sites that can be tested with other pharmacological libraries.
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research